Title A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children 617 Years of Age with Urea Cycle Disorders, with a Long-Term Safety Extension (Hyperion Protocol HPN-100-005). FDA Phase II Clinical Study.
Grant Recipient(s)
Grant Recipient(s)
Name J Lawrence Merritt II, MD
URL J Lawrence Merritt II, MD
Granted By Hyperion Inc.
Awarded Date 8 6 2009 To 8 4 2011
The major goal of this project is study the new experimental drug, HPN-100, to study the safety and tolerability of HPN-100 in children with urea cycle disorders.